Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Outcomes for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results